tcc schreef op 14 november 2017 07:46:
Pharming Group NV (OTC:PHGUF) Given “Buy” Rating at HC Wainwright
Posted by Joyce Ramirez on Nov 14th, 2017 // No Comments
Pharming Group NV logoHC Wainwright reissued their buy rating on shares of Pharming Group NV (OTC:PHGUF) in a research note released on Thursday, October 26th.
Pharming Group NV (OTC:PHGUF) traded up $0.01 during trading hours on Thursday, hitting $1.49. 17,000 shares of the stock were exchanged, compared to its average volume of 68,706. Pharming Group NV has a 1 year low of $0.25 and a 1 year high of $1.56. The company has a debt-to-equity ratio of 11.72, a quick ratio of 1.27 and a current ratio of 1.77.
About Pharming Group NV
Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.
Receive News & Ratings for Pharming Group NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group NV and related companies with MarketBeat.com's FREE daily email newsletter.